Table 3.
Clinical studies, antimicrobial therapies, and outcomes for patients infected with MβL-producing K. pneumoniae
| Reference | Country (yr of publication) | Study design | No. of patients with indicated type of infection | Type of MBL (no. of isolates) | Treatment (no. of patients) | Outcome (no. of successes/no. of failures) |
|---|---|---|---|---|---|---|
| 121 | Greece (2004) | Case reports | 4 (2 BSIs, 1 case of mediastinitis, 1 bone infection) | VIM-1 (4) | Colistin (1) | 1/0 |
| 86 | Greece (2008) | Tigecycline (1) | 1/0 | |||
| 56 | Spain (2008) | Tigecycline-colistin (2) | 1/1 | |||
| 223 | Ireland (2010) | |||||
| 269 | Taiwan (2001) | Case series | 3 BSIs | IMP-8 (3) | Carbapenem (3) | 1/2 |
| 143 | Taiwan (2004) | Case series | 3 (2 pneumonias, 1 BSI) | IMP-type enzyme (3) | Carbapenem (1) | 1/0 |
| Carbapenem-aminoglycoside (2) | 2/0 | |||||
| 240 | Greece (2008) | Case series | 17 (14 BSIs, 3 pneumonias) | VIM-1 (17) | Colistin (6) | 6/0 |
| Tigecycline (1) | 0/1 | |||||
| Colistin-aminoglycoside (2) | 2/0 | |||||
| Colistin doxycycline (1) | 0/1 | |||||
| Carbapenem-colistin (6) | 5/1 | |||||
| Carbapenem-aminoglycoside-doxycycline (1) | 1/0 | |||||
| 175 | Greece (2010) | Case-control study | 18 BSIs | VIM-1 (17) | Colistin (10) | 6/4 |
| VIM-type enzyme (1) | Colistin-aminoglycoside (8) | 4/4 | ||||
| 64 | Greece (2007) | Retrospective study | 28 BSIs | VIM-1 (28) | Carbapenem (8) | 7/1 |
| Colistin (4) | 0/4 | |||||
| Aminoglycoside (3) | 2/1 | |||||
| Carbapenem-aminoglycoside (6) | 6/0 | |||||
| Carbapenem-colistin (1) | 1/0 | |||||
| Aztreonam-aminoglycoside (2) | 1/1 | |||||
| No active drug (4) | 2/2 | |||||
| 67 | Greece (2009) | Prospective observational study | 67 BSIs | VIM-1 (67) | Carbapenem (14) | 11/3 |
| Carbapenem-colistin (8) | 8/0 | |||||
| Carbapenem-aminoglycoside (4) | 3/1 | |||||
| Colistin (15) | 11/4 | |||||
| Aminoglycoside (8) | 5/3 | |||||
| No active drug (18) | 13/5 |